M
Malcolm K. Brenner
Researcher at Center for Cell and Gene Therapy
Publications - 632
Citations - 50064
Malcolm K. Brenner is an academic researcher from Center for Cell and Gene Therapy. The author has contributed to research in topics: Antigen & Cytotoxic T cell. The author has an hindex of 109, co-authored 606 publications receiving 45233 citations. Previous affiliations of Malcolm K. Brenner include St. Jude Children's Research Hospital & Northwick Park Hospital.
Papers
More filters
Journal ArticleDOI
Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation
Xiaoou Zhou,Gianpietro Dotti,Robert A. Krance,Caridad Martinez,Swati Naik,Rammurti T. Kamble,April G. Durett,Olga Dakhova,Barbara Savoldo,Antonio Di Stasi,David M. Spencer,Yu Feng Lin,Hao Liu,Bambi Grilley,Adrian P. Gee,Cliona M. Rooney,Helen E. Heslop,Malcolm K. Brenner +17 more
TL;DR: Alloreplete iC9-T cells can reconstitute immunity posttransplant and administration of CID can eliminate them from both peripheral blood and the central nervous system (CNS), leading to rapid resolution of GVHD and CRS.
Journal ArticleDOI
Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory t cells without diminishing antiviral and antileukemic activity
Alana A. Kennedy-Nasser,Stephanie Ku,Paul Castillo-Caro,Yasmin Hazrat,Meng Fen Wu,Hao Liu,Jos Melenhorst,A. John Barrett,Sawa Ito,Aaron E. Foster,Barbara Savoldo,Eric Yvon,George Carrum,George Carrum,Carlos A. Ramos,Carlos A. Ramos,Robert A. Krance,Robert A. Krance,Kathryn S. Leung,Helen E. Heslop,Helen E. Heslop,Malcolm K. Brenner,Malcolm K. Brenner,Catherine M. Bollard,Catherine M. Bollard +24 more
TL;DR: ULD IL-2 is well tolerated, expands a Treg population in vivo, and may be associated with a lower incidence of viral infections and GVHD.
Journal ArticleDOI
Adoptive T cell therapy of cancer.
TL;DR: Current research focuses on defining the optimum type of cell for transfer, genetically modifying infused T cells to augment function and overcome tumor evasion strategies and modulating the host environment.
Journal ArticleDOI
Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
Thomas Shum,Thomas Shum,Bilal Omer,Bilal Omer,Haruko Tashiro,Robert L. Kruse,Robert L. Kruse,Dimitrios L. Wagner,Kathan Parikh,Zhongzhen Yi,Tim Sauer,Daofeng Liu,Robin Parihar,Paul Castillo,Hao Liu,Malcolm K. Brenner,Malcolm K. Brenner,Leonid S. Metelitsa,Stephen Gottschalk,Cliona M. Rooney +19 more
TL;DR: The constitutively signaling C7R system developed here delivers potent IL7 stimulation to CAR T cells, increasing their persistence and antitumor activity against multiple preclinical tumor models, supporting its clinical development.
Journal ArticleDOI
Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes
Concetta Quintarelli,Juan F. Vera,Barbara Savoldo,Greta Maria Paola Giordano Attianese,Martin Pule,Aaron E. Foster,Helen E. Heslop,Cliona M. Rooney,Malcolm K. Brenner,Gianpietro Dotti +9 more
TL;DR: The incorporation of an inducible caspase-9 suicide gene allowed efficient elimination of transgenic CTLs after exposure to a chemical inducer of dimerization, thereby increasing the safety and feasibility of the approach.